EPS Corporation and Emerald Clinical to Co-Host Webinar on Accelerating APAC Oncology Developmen

EPS Corporation and Emerald Clinical Trials will co-host a webinar on Tuesday, September 22, 2026, focusing on accelerating oncology drug development across the Asia-Pacific (APAC) region.

Webinar OverviewRegistration is now open for our webinar on accelerating oncology development across the Asia-Pacific (APAC) region.

For biotech companies, delays in development timelines and increasing costs resulting from conducting development sequentially across different regions have become significant challenges. In recent years, more companies have adopted integrated development approaches across  China and Japan as part of a unified APAC strategy to accelerate proof of concept, reduce redundant studies, and expedite global development.

In this webinar, experienced experts in oncology development and regulatory affairs will share practical strategies for successfully conducting parallel development across key APAC markets.

Who Should Attend

This webinar is recommended for:

• Professionals involved in global oncology development strategy
• Clinical development professionals
• Professionals involved in portfolio strategy and development planning
• Professionals responsible for regulatory strategy and execution
• Those interested in learning practical approaches to parallel development across APAC markets

What You Will Learn

• Why APAC should be integrated into global oncology development strategies
• Regulatory considerations and development planning in China and Japan, including NMPA and PMDA perspectives, IND submissions, and GCP requirements
• Key considerations for site selection and successful study execution
• Common challenges in oncology development and approaches to addressing them
• Key factors for evaluating whether an integrated APAC development strategy is appropriate for your asset

You'll walk away with practical insights on building a unified Asia-Pacific strategy that supports Phase II/III development, minimizes unnecessary bridging studies, and helps maximize asset value.

Please note:

• This webinar is intended for professionals at pharmaceutical companies and other organizations engaged in the pharmaceutical business. Registrations from CROs and other companies deemed to be in a competing business may be declined.
• A corporate or institutional email address is required to register.
• Registrations submitted with free email addresses (e.g., Gmail) cannot be accepted.
   

Luke Gill, VP, Global Head of Oncology, Emerald Clinical
Will Chen, Head of Regulatory Affairs, Emerald Clinical
Rokuya Nochi, Executive Officer, EPS Corporation